{"nctId":"NCT00975715","briefTitle":"Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures","startDateStruct":{"date":"2009-09"},"conditions":["Partial Onset Seizures"],"count":99,"armGroups":[{"label":"TRI476","type":"EXPERIMENTAL","interventionNames":["Drug: TRI476","Drug: Benzodiazepines"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to TRI476","Drug: Benzodiazepines"]}],"interventions":[{"name":"TRI476","otherNames":[]},{"name":"Placebo to TRI476","otherNames":[]},{"name":"Benzodiazepines","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female outpatients, aged 4 to 14 years (inclusive), with a minimum body weight of 15 kg.\n* A diagnosis of partial onset seizures, which include the seizure subtypes of simple, complex, and secondarily generalized seizures (based on the International League Against Epilepsy (ILAE) Classification, as modified in 1981).\n\nExclusion Criteria:\n\n* A document history of generalized status epileptics in the past 6 months.\n* Seizures having a metabolic, neoplastic, or active infectious origin.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Partial Onset Seizure Frequency Per 28 Days From Baseline to the Double-blind Phase, by Treatment Group","description":"Percent change in partial onset seizure frequency per 28 days during the double-blind phase from the screening phase, was calculated according to the following formula: \"Percent change in partial onset seizure frequency per 28 days from the screening phase\" = (partial onset seizure frequency per 28 days during the double-blind phase - partial onset seizure frequency per 28 days during the screening phase) / partial onset seizure frequency per 28 days during the double-blind phase x 100 \"Partial onset seizure frequency per 28 days\" = Number of partial onset seizures during each phase (screening phase or double-blind phase) / number of days during the screening or double-blind phase Ã— 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"63.546"},{"groupId":"OG001","value":"14.82","spread":"73.333"}]}]}]},{"type":"SECONDARY","title":"Partial Seizure Frequency Per 28 Days, by Study Period (Every 28 Days) and Treatment Group","description":"Partial onset seizure frequency per 28 days during a period between baseline and Week 4 was measured. Partial onset seizure frequency per 28 days (count/28 days)\" = Number of partial onset seizures during each phase (screening phase or double-blind phase) / Number of days during the phase x 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.58","spread":"109.457"},{"groupId":"OG001","value":"90.61","spread":"283.187"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.40","spread":"70.209"},{"groupId":"OG001","value":"98.73","spread":"291.781"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Response During Double-blind Phase, by Treatment Group","description":"Responder rate was defined as the percent of participants with an at least 50% reduction in partial onset seizure frequency per 28 days from the screening phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Partial Onset Seizure Frequency During the Double-blind Phase by Seizure Type","description":"Percent change in seizure frequency from baseline = 100 (T-B)/B, B=Seizure frequency per 28 days during baseline phase, T=Seizure frequency per 28 days during the double-blind phase. Seizure frequency per 28 days is calculated as: (seizure frequency during the double-blind phase / the number of days the seizure information were provided) x 28. Only patients with both baseline and corresponding post-baseline values are included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.73","spread":"51.329"},{"groupId":"OG001","value":"-16.89","spread":"45.822"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.86","spread":"78.583"},{"groupId":"OG001","value":"30.59","spread":"91.551"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.54","spread":"64.660"},{"groupId":"OG001","value":"12.11","spread":"82.879"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Global Impression of Change (CGIC) at Final Assessment, by Treatment Group","description":"Clinical Global Impression of Change (CGI) is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). CGI-C scores range from 1 (very much improved) through to 7 (very much worse).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Somnolence","Nasopharyngitis","Upper respiratory tract infection","Vomiting","Rash"]}}}